Xbrane Biopharma: Ximluci Approved in the EU - Redeye

Redeye leaves a short comment on today’s news that Xbrane and STADA have secured EU approval for Ximluci. Today’s announcement was expected, but it nevertheless marks a significant milestone for the company, and the Q1 2023 launch is nearing swiftly.

Länk till analysen i sin helhet: https://www.redeye.se/research/862858/xbrane-biopharma-ximluci-approved-in-the-eu?utm_source=finwire&utm_medium=RSS